ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2016
Phenotypic transformation of intimal and adventitial lymphatics in atherosclerosis: a regulatory role for soluble VEGF receptor 2.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Integrated analyses of single-cell transcriptome and mendelian randomization reveal the role of lymphatic endothelial CD74 in the progression of atherosclerosis.Journal of geriatric cardiology : JGC · 2026Article
- Lymphangiogenesis in hypercholesterolemic skin: A comparative study of xanthomatous and non-xanthomatous lesions.JID innovations : skin science from molecules to population health · 2026Article
- Targeting lymphatic dysfunction in atherosclerosis: a state-of-the-art review on potential therapies and future directions.Frontiers in cardiovascular medicine · 2026Review
- Article
- Atherosclerosis increases adventitial pressure and limits solute transport via fluid-balance mechanisms.Biomechanics and modeling in mechanobiology · 2025Article
- Promising Adventitia in Atherosclerosis.Current vascular pharmacology · 2025Review
- Association between metformin treatment and coronary artery inflammation based on pericoronary adipose tissue attenuation in type 2 diabetes mellitus patients.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Coronary inflammation based on pericoronary adipose tissue attenuation in type 2 diabetic mellitus: effect of diabetes management.Cardiovascular diabetology · 2024Article
- The Role of VEGF Family in Lipid Metabolism.Current pharmaceutical biotechnology · 2023Article
- Lymphatic Vessel Regression and Its Therapeutic Applications: Learning From Principles of Blood Vessel Regression.Frontiers in physiology · 2022Review
- Role of R-spondin 2 in arterial lymphangiogenesis and atherosclerosis.Cardiovascular research · 2021Article
- Oxidatively Modified LDL Suppresses Lymphangiogenesis via CD36 Signaling.Antioxidants (Basel, Switzerland) · 2021Article
- Downregulation of NAGLU in VEC Increases Abnormal Accumulation of Lysosomes and Represents a Predictive Biomarker in Early Atherosclerosis.Frontiers in cell and developmental biology · 2021Article
- Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?Frontiers in cardiovascular medicine · 2021Review
- Efficient aortic lymphatic drainage is necessary for atherosclerosis regression induced by ezetimibe.Science advances · 2020Article
- Article
- Serum sLYVE-1 is not associated with coronary disease but with renal dysfunction: a retrospective study.Scientific reports · 2019Article
- The CD44-HA axis and inflammation in atherosclerosis: A temporal perspective.Matrix biology : journal of the International Society for Matrix Biology · 2019Review
- Arterial Lymphatics in Atherosclerosis: Old Questions, New Insights, and Remaining Challenges.Journal of clinical medicine · 2019Review
- Cardiac lymphatics in health and disease.Nature reviews. Cardiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
The role of lymphatics in atherosclerosis is not yet understood. Here, we investigate lymphatic growth dynamics and marker expression in atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice. The prolymphangiogenic growth factor, VEGF-C, was elevated in atherosclerotic aortic walls. Despite increased VEGF-C, we found that adventitial lymphatics regress during the course of formation of atherosclerosis (P < 0.01). Similar to lymphatic regression, the number of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1(+)) macrophages decreased in the aortic adventitia of apoE(-/-) mice with atherosclerosis (P < 0.01). Intimal lymphatics in the atherosclerotic lesions exhibited an atypical phenotype, with the expression of podoplanin and VEGF receptor 3 (VEGFR-3) but not of LYVE-1 and prospero homeobox protein 1. In the aortas of atherosclerotic animals, we found markedly increased soluble VEGFR-2. We hypothesized that the elevated soluble VEGFR-2 that was found in the aortas of apoE(-/-) mice with atherosclerosis binds to and diminishes the activity of VEGF-C. This trapping mechanism explains, despite increased VEGF-C in the atherosclerotic aortas, how adventitial lymphatics regress. Lymphatic regression impedes the drainage of lipids, growth factors, inflammatory cytokines, and immune cells. Insufficient lymphatic drainage could thus exacerbate atherosclerosis formation. Our study contributes new insights to previously unknown dynamic changes of adventitial lymphatics. Targeting soluble VEGFR-2 in atherosclerosis may provide a new strategy for the liberation of endogenous VEGF-C and the prevention of lymphatic regression.-Taher, M., Nakao, S., Zandi, S., Melhorn, M. I., Hayes, K. C., Hafezi-Moghadam, A. Phenotypic transformation of intimal and adventitial lymphatics in atherosclerosis: a regulatory role for soluble VEGF receptor 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.